US Stock MarketDetailed Quotes
OKYO OKYO Pharma
- 1.660
- +0.075+4.73%
Close Jul 19 16:00 ET
55.17MMarket Cap-3192P/E (TTM)
1.740High1.570Low48.85KVolume1.640Open1.585Pre Close80.49KTurnover0.28%Turnover RatioLossP/E (Static)33.24MShares3.07052wk High-26.77P/B29.46MFloat Cap1.09052wk Low--Dividend TTM17.75MShs Float7.000Historical High--Div YieldTTM10.73%Amplitude0.920Historical Low1.647Avg Price1Lot Size
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg
OKYO Pharma Stock Forum
OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
OKYO Pharma is set to begin a Phase 2 clinical trial of OK-101 for treating neuropathic corneal pain (NCP) in Q3 2024. This is the first instance of an FDA IND clearance for a drug targeting NCP, a significant unmet medical need. OK-101 has shown statistically significant pain relief in previous trials for dry eye disease and preclinical models of NCP. The 12-week, placebo-controlled trial will be led ...
Dry Eye Disease (DED) is a prevalent condition affecting millions globally, characterized by discomfort, visual disturbance, and potential damage to the ocular surface. Despite the availability of various treatments, many patients continue to seek more effective solutions. In a significant development, OKYO Pharma has announced that its drug, OK-101, has achie...
No comment yet